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Abstract
The cellular pathways activated by mutant prion protein (PrP) in genetic prion diseases, ultimately leading to neuronal
dysfunction and degeneration, are not known. Several mutant PrPs misfold in the early secretory pathway and reside longer
in the endoplasmic reticulum (ER) possibly stimulating ER stress-related pathogenic mechanisms. To investigate whether
mutant PrP induced maladaptive responses, we checked key elements of the unfolded protein response (UPR) in transgenic
mice, primary neurons and transfected cells expressing two different mutant PrPs. Because ER stress favors the formation of
untranslocated PrP that might aggregate in the cytosol and impair proteasome function, we also measured the activity of
the ubiquitin proteasome system (UPS). Molecular, biochemical and immunohistochemical analyses found no increase in
the expression of UPR-regulated genes, such as Grp78/Bip, CHOP/GADD153, or ER stress-dependent splicing of the mRNA
encoding the X-box-binding protein 1. No alterations in UPS activity were detected in mutant mouse brains and primary
neurons using the Ub
G76V-GFP reporter and a new fluorogenic peptide for monitoring proteasomal proteolytic activity in
vivo. Finally, there was no loss of proteasome function in neurons in which endogenous PrP was forced to accumulate in the
cytosol by inhibiting cotranslational translocation. These results indicate that neither ER stress, nor perturbation of
proteasome activity plays a major pathogenic role in prion diseases.
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Introduction
Prion diseases are fatal degenerative disorders of the central
nervous system (CNS) that can arise sporadically, be genetically
inherited, or acquired through infection [1,2]. The key pathogenic
event is conversion of the cellular prion protein (PrP
C) into a self-
propagating aberrant conformer (PrP
Sc) [1], which induces
neurodegeneration through an unknown mechanism [3]. PrP
C is
a glycosylphosphatidylinositol (GPI) membrane-anchored glyco-
protein of uncertain function, mainly expressed by neurons in the
CNS [4]. Like most membrane-associated proteins, PrP
C is
cotranslationally translocated into the endoplasmic reticulum
(ER), where it undergoes oxidative folding and facultative N-
linked glycosylation. After transit in the Golgi, PrP
C is delivered to
the cell surface, where it resides in lipid rafts. Cell surface PrP
C can
be released into the extracellular space, or internalized to an
endosomal compartment, from which it is either recycled to the
plasma membrane or diverted to lysosomes for degradation [5].
Mutations in the gene encoding PrP
C are responsible for
genetic prion diseases, which include familial Creutzfeldt-Jakob
disease (fCJD), Gerstmann-Stra ¨ussler-Scheinker (GSS) syndrome
and fatal familial insomnia (FFI) [6,7]. These diseases are
inherited in an autosomal dominant fashion and are thought to
be due to a toxic effect of misfolded mutant PrP molecules [3].
Tg(PG14) mice expressing the mouse PrP homologue of a 72-
amino acid insertion associated with a mixed CJD-GSS
phenotype develop a progressive neurological illness character-
ized by ataxia and massive apoptosis of cerebellar granule
neurons [8,9]. Tg(CJD) mice carrying the mouse PrP homologue
of the D178N/V129 PrP mutation (moPrP D177N/V128)
develop key features of fCJD, including cognitive, motor and
neurophysiological abnormalities [10]. Tg(PG14) and Tg(CJD)
mice synthesize in their brains misfolded forms of mutant PrP
with biochemical properties reminiscent of PrP
Sc,i n c l u d i n g
insolubility in non-denaturing detergents, and resistance to mild
proteinase-K (PK) digestion [8,10]. Analysis of PG14 and
D177N/V128 metabolism and localization in cultured neurons
showed that the biosynthetic maturation of these mutants in the
ER is delayed, and they accumulate abnormally in this organelle
[10,11,12]. This suggests that perturbation of ER homeostasis
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role.
The ER has a robust quality control system that prevents
misfolded and mismodified proteins from exiting the ER and being
transported through the secretory pathway. This system includes
chaperones and folding catalysts that form a matrix on which
newly synthesized proteins attain their final conformation [13].
When protein misfolding occurs and unfolded proteins accumulate
and aggregate in the ER, cells experience ‘‘ER stress’’ and activate
an adaptive signal transduction pathway, known as the unfolded
protein response (UPR). The UPR enhances the folding capacities
in the ER, improves protein disposal through ER-associated
degradation (ERAD), and reduces the rate of protein synthesis and
translocation into the ER lumen [14].
The UPR signals through three distinct ER stress sensors on the
ER membrane [15]. One is IRE1a (inositol-requiring transmem-
brane kinase and endonuclease), a type I ER transmembrane
protein whose cytoplasmic region carries protein kinase and
endoribonuclease domains. In ER-stressed cells IRE1a multi-
merizes and autophosphorylates, setting in motion its RNAse
activity. Activated IRE1a initiates the unconventional splicing of
the mRNA encoding the transcriptional factor X-box-binding
protein 1 (XBP1) to produce sXBP1, a more stable form of XBP1
with a potent transactivator domain that enhances transcription of
genes involved in protein folding, secretion and ERAD [16].
Another ER stress sensor is the activating transcription factor 6
(ATF6) [17]. This is a type II ER transmembrane protein whose
cytosolic domain contains a bZIP transcriptional factor. When
protein misfolding and accumulation occur, ATF6 is transported
to the Golgi where it is processed within the transmembrane
domain to release the cytosolic domain, which translocates to the
nucleus and induces expression of the ER chaperone Grp78/BiP,
and XBP1. Therefore, the IRE1a and ATF6 signaling pathways
merge through regulation of XBP1 activity [18].
The third sensor is the ER-associated kinase PERK (double-
stranded RNA-activated protein kinase-like ER kinase), which
phosphorylates the a subunit of eukaryotic translation initiation
factor 2 (eIF2a). This inhibits protein translation, reducing the
overload of misfolded proteins. This pathway also activates ATF4,
a transcription factor that induces expression of CHOP/
GADD153, which can trigger apoptosis when cells unable to
handle the unfolded protein load become irreversibly damaged.
Thus, persistent ER stress eventually leads to cell death.
In this study we explored the role of ER stress in genetic prion
diseases by measuring the levels of key elements of the UPR in
brain tissue and primary neurons from Tg(PG14) and Tg(CJD)
mice, and in transfected cells expressing mutant PrP under the
control of a tetracycline-inducible promoter. Because ER stress
favors formation of a cytosolic pool of untranslocated PrP [19,20]
that might aggregate and inhibit proteasome activity [21], we also
examined the function of the ubiquitin-proteasome system (UPS)
in the transgenic models, and in neurons in which PrP
C was forced
to accumulate in the cytosol by interference with the correct
insertion of the PrP signal peptide into the translocon.
Results
ER Stress Markers in Transgenic Mice and Primary
Neuronal Cultures
To test whether mutant PrP expression triggered toxic response
pathways in the ER, we analyzed the splicing of XBP1 mRNA
transcripts and the levels of Grp78/BiP, Grp58/Erp57 and
CHOP/GADD153 in the brains of Tg(PG14) and Tg(CJD) mice
at different stages of their neurological illness. Tg(PG14) mice
develop a slowly progressive neurological syndrome characterized
neuropathologically by synaptic loss in the molecular layer of the
cerebellum and massive apoptosis of cerebellar granule neurons
[8,9,22]. They develop ataxia, kyphosis and foot clasp reflex at
,240 days of age and die at ,450 days [8,9]. Tg(CJD) mice
develop alterations of spatial working memory between 200 and
320 days of age, electroencephalographic abnormalities at $360
days, and a motor syndrome involving alterations of motor
coordination and body posture that is first seen at ,450 days and
increases in severity as the mice age [10]. Consistent neuropath-
ological findings in Tg(CJD) mice are loss of calretinin-positive
neurons in the hippocampus and neocortex, and ER swelling with
accumulation of mutant PrP in cerebellar granule neurons [10].
ER stress markers were analyzed in a total of 23 Tg(PG14) mice
aged 23, 24, 36, 102, 120, 124, 131, 146, 171, 172, 189, 210, 214,
226, 240, 241, 296, 364, 372, 377, 404, 405 and 409 days, and five
Tg(CJD) mice at 81, 338, 411, 421 and 814 days. RNA and
proteins were extracted from the whole brain or specific brain
regions showing pathological changes (the cerebellum in Tg(PG14)
mice, and the cerebral cortex, hippocampus and cerebellum in
Tg(CJD) mice). Non-Tg littermates and age-matched Tg(WT)
mice expressing wild-type PrP [8] were used as controls.
XBP1 splicing was readily detected in the liver of mice and in
cells treated with tunicamycin, which induces ER stress by
perturbing the folding efficiency in the ER, whereas no splicing
was observed in the whole brain or dissected brain regions of the
mutant mice at any stage of their disease (Fig. 1A-C and data not
shown). There was no increase in the levels of Grp78/BiP or
CHOP/GADD153 transcripts, assessed by Northern blot (not
shown), or Grp58/Erp57 and Grp78/BiP proteins by Western
blot of brain extracts (Fig. 2A–D).
In a final set of experiments, we used immunohistochemical
techniques to visualize UPR activation in brain sections of four
Tg(PG14) mice aged 145, 180 and 367 (two mice) days, and two
Tg(CJD) mice aged 542 and 751 days. As a positive control for the
staining, Grp78/BiP and CHOP/GADD153 were readily detect-
ed in colon adenocarcinoma biopsies (Fig. 3A and D) [23,24]. No
increase in immunoreactivity was seen in the brains of Tg(PG14)
and Tg(CJD) mice compared to age-matched Non-Tg and
Tg(WT) controls, not even in the regions undergoing pathological
changes (Fig. 3C and F).
The fact that we detected no proximal UPR signaling in the
brain might be due to transient and/or not synchronized UPR
activation. Therefore we analyzed UPR markers in primary
cultures of CGN from Tg(CJD) mice, which show dramatic ER
swelling associated with retention of mutant PrP [10]. No XBP-1
splicing was observed in CGN from the mutant mice, unless cells
were treated with tunicamycin (Fig. 1D). There was also no
difference in Grp78/BiP protein levels between control and
mutant CGN (Fig. 2E and F).
ER Stress in PC12 Cells Expressing Mutant PrP Under the
Control of an Inducible Promoter and in Transiently
Transfected HEK-293 cells
To exclude that cells unresponsive/resistant to the effect of the
mutant protein were selected in culture, we developed lines of
transfected cells in which PrP expression was activated after clonal
selection. We used pheochromocytoma PC12 cells, which respond
to nerve growth factor (NGF) by stopping division and developing
the morphological, electrophysiological and neurochemical prop-
erties of neurons [25]. PC12 cells constitutively expressing the
reverse tetracycline-controlled transactivator (PC12 Tet-on) [26]
were transfected with an expression vector in which the PrP cDNA
was under the control of the tetracycline-responsive element
Prion, ER Stress and the Proteasome
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inducer doxycycline (dox), cells were co-transfected with a plasmid
encoding the tet-control transcriptional silencer which blocks
transcription of genes under control of the TRE in the absence of
dox. We generated PC12 Tet-on cell lines expressing PG14 and
D177N/V128, as well as D177N/M128 PrP whose human
homolog is associated with FFI. As controls, we produced lines
expressing mouse wild-type PrP (M128), and M128V PrP to model
the non-pathogenic V129 polymorphic variant of human PrP.
PC12 Tet-on cells had tightly regulated expression of PrP,
which was undetectable in the absence of dox, and which
increased progressively with increasing dox concentrations
(Fig. 4A). PrP expression was detected after 8 h of induction,
and lasted at least 96 h (Fig. 4B). Most PC12 clones displayed
maximal transgenic PrP expression (approximately double endog-
enous PrP) in response to 1–2 mg/ml dox (not shown).
Mutant PrPs were insoluble in non-denaturing detergents
(Fig. 5A; percentages of PrP in the pellet were: 68612 for
PG14; 4468.2 for D177N/M128; 47610.5 for D177N/V128;
n=5), and were weakly protease-resistant, in contrast to the
solubility and protease-sensitivity of WT and M128V PrPs (Fig 5A
and B, and data not shown). Consistent with previous observations
[27], neuronal differentiation of PC12 cells on exposure to NGF
did not modify the proportion of detergent-insoluble PrP or its
level of protease resistance (not shown). The mutant PrPs
expressed in PC12 Tet-on cells were found at lower levels on
the cell surface, and had an intense intracellular distribution
(Fig. 6A and B), which colocalized in part with the ER marker
calnexin (Fig. 6C). Thus PG14 and D177N PrPs misfolded and
were partially retained in the ER of PC12 Tet-on cells, confirming
similar observations in primary neurons [10,12], and validating
this cell model for investigating the effect of acute mutant PrP
expression on ER homeostasis.
The levels of Grp78/BiP and CHOP/GADD153 mRNAs were
analyzed inPC12 Tet-oncellsbeforeand afterinductionwith1 mg/
mldoxfor24 h.PrPexpressiondidnotincreasethe amountofthese
transcripts (Fig. 7A and B). There was also no difference in Grp78/
BiP protein levels between control and mutant cells (not shown).
IRE1a-dependent splicing of XBP1 mRNA was then assessed in
cells treated with tunicamycin and/or dox. The spliced form of
XBP1 was readily detectable after tunicamycin, but not in cells
exposed only to dox (Fig. 7C). The same analysis on cells treated
with dox for 96 h showed no evidence of ER stress (not shown).
It was possible that only a limited number of cells accumulated
sufficient amounts of mutant PrP in the ER to activate the ER
stress response. If this were the case, analysis of total RNA
extracted from whole cultures could contain low levels of Grp78/
BiP, CHOP/GADD153 and XBP1 transcripts. To directly test
whether UPR markers were activated in cells accumulating high
PrP levels, mutant PrP-transfected cells were treated with dox or
tunicamycin then immunostained with anti-PrP and anti-CHOP/
GADD153 antibodies. There was no activation of CHOP/
GADD153 in cells accumulating high intracellular PrP levels
(Fig. 7D, panels a and b); as expected, cells treated with
Figure 1. Analysis of XBP1 splicing in mutant PrP transgenic mice and primary neurons. (A) Total RNA was extracted from the whole brain
of two male Non-Tg (lanes 1 and 2), two female Tg(WT) (lane 3 and 4), one presymptomatic female (lane 5) and one clinically ill male (lane 6) Tg(PG14)
mice of the ages indicated, and analyzed by RT-PCR. XBP1 splicing was determined from the appearance of rapidly migrating spliced XBP1 in
tunicamycin (Tm)-treated PC12 cells (PC, lane 7) or in the liver of a Non-Tg mouse intraperitoneally injected with tunicamycin (1 mg per gram of body
weight) and analyzed 96 h later (Liv, lane 8). The arrows point to unspliced (uXBP1) and spliced (sXBP1) transcripts. (B) XBP1 splicing was analyzed in
whole brain (Br) or cerebellum (Cb) of a male Tg(WT) (WT, lanes 1 and 3) and a female Tg(PG14) mouse with early signs of neurological disease (PG,
lanes 2 and 4), aged 260 and 240 days respectively. Cultured cerebellar granule neurons from C57BL/6J mice treated with Tm were used as positive
control (CGN, lane 5). (C) Total RNA was extracted from the hippocampus (Hipp), cerebral cortex (Cx) and cerebellum (Cb) of a 411-day-old female
(lanes 1, 5 and 9), and a 421-day-old male (lanes 2, 6 and 10) Tg(CJD-A21) mouse (CJD), a 448-day-old female Non-Tg mouse (NT, lanes 3, 7 and 11)
and a 341-day-old female Tg(WT) mouse (WT, lanes 4, 8 and 12). Tm-treated cerebellar granule neurons (CGN) were used as control (lane 13). (D) CGN
from Non-Tg (NT) and Tg(CJD) mice were cultured for 7 days, and either left untreated (2) or treated (+) with 5 mg/ml Tm for 8 h before analysis of
XBP1 splicing. This result is representative of two independent experiments. Size markers are given in base-pairs.
doi:10.1371/journal.pone.0019339.g001
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GADD153 induction (Fig. 7D, panel c).
Finally, we analyzed ER stressmarkers in a different cell model of
acute mutant PrP expression. HEK-293 cells were transfected with
an empty pcDNA3.1 plasmid or with plasmids encoding WT,
PG14, D177N/M128 or D177N/V128 PrP. As positive controls
cells were transfected with a plasmid encoding murine Ig-m-chains,
which in the absence of Ig-L chains accumulate in the ER inducing
a robust UPR ([28,29] and T. Anelli, R. Ronzoni and R.S.,
unpublished results), or were treated with tunicamycin. Cells were
lysed 24 h after transfection to monitor PrP and m-chain expression
and XBP1 mRNA splicing. PrP and m-chains were efficiently
expressedinHEK-293 cells(Fig.S1Aand B).XBP1 mRNAsplicing
was readily detected in m-chain expressing cells or after treatment
with tunicamycin, but not in mutant PrP-expressing cells (Fig. S1C).
Thus, although HEK-293 cells respond normally to misfolded
protein accumulation in the ER by up-regulating the UPR system,
mutant PrPs did not evoke this response.
Mutant PrP Mice or Neurons Accumulating Cytosolic PrP
Show no Functional Impairment of Ubiquitin-dependent
Proteasomal Degradation
It has been suggested that misfolded PrP might be recognized as
abnormal by the ER quality control machinery and retrogradely
translocated into the cytosol for proteasomal degradation (ER-
associated degradation, ERAD, pathway) [30,31]. In Tg(PG14)
mice, mutant PrP accumulates continuously as the animals age
and granule neurons in the cerebellum die [9]. To test whether
accumulation of mutant PrP in Tg(PG14) mice was associated with
reduced proteasome function, we generated double-transgenic
mice co-expressing PG14 PrP and a green fluorescent protein
(GFP) reporter substrate of the UPS (Ub
G76V-GFP) [32]. The
Ub
G76V-GFP transgene is under the transcriptional control of the
b-actin promoter, which drives constitutive expression in all
organs. Under physiological conditions the N-terminal ubiquitin
moiety of Ub
G76V-GFP is recognized as a degradation signal and
poly-ubiquitinated, leading to constitutive proteosomal degrada-
tion of GFP. An alteration of the UPS therefore results in
accumulation of Ub
G76V-GFP. Expression of this reporter in vivo
has been used to assess the UPS function in prion-infected mice
[21], and in transgenic mouse models of polyglutamine disease
and amyotrophic lateral sclerosis [33,34,35].
Tg(PG14) mice were crossed with two independent lines of
Ub
G76V-GFP mice (Ub
G76V-GFP1 and Ub
G76V-GFP2), which
have different basal levels of reporter expression, to produce
Tg(PG14
+/-)/Ub
G76V-GFP
+/2 mice, and the Tg(PG14
2/2)/
Ub
G76V-GFP
+/2 and Tg(PG14
+/2)/Ub
G76V-GFP
2/2 controls.
As an additional control, we generated Tg(WT
+/2)/Ub
G76V-
GFP
+/2 mice, expressing transgenically-encoded wild-type PrP.
Figure 2. The ER stress-regulated chaperones Grp78/BiP and Grp58/Erp57 are not induced in the brain and primary neurons from
mutant PrP mice. (A) Protein extracts (20 mg) from the whole brain (Br) or cerebellum (Cb) of a 358-day-old male Tg(WT) and a terminally ill 363-
day-old male Tg(PG14) mouse were analyzed by Western blot with anti-KDEL and anti-actin antibodies. The anti-KDEL antibody detects a band at
,78 kDa corresponding to Grp78/BiP. Molecular mass markers are in kilodaltons. (B) Grp78/BiP was quantified by densitometic analysis of Western
blots like the one shown in A, normalized for the level of actin, and expressed as a percentage of the level in Tg(WT) mice. Each bar indicates the
mean 6 SEM of three animals. (C) Protein extracts (20 mg) from the hippocampus (Hipp), cerebral cortex (Cx) and cerebellum (Cb) of a 323-day-old
male Tg(WT) and a 338-day-old male Tg(CJD) mouse were analyzed by Western blot with anti-Grp58/Erp57 and anti-actin antibodies. (D) Grp58/Erp57
level was quantified by densitrometic analysis of Western blots, as shown in C, normalized for the level of actin, and expressed as a percentage of the
level in Tg(WT) mice. Each bar indicates the mean 6 SEM of three animals. (E) Protein extracts of cerebellar granule neurons (CGN) from Non-Tg (NT)
and Tg(CJD) mice were immunoblotted with anti-KDEL and anti-actin antibodies. CGN from C57BL/6 mice were treated with tunicamycin (Tm) as
positive control. (F) Grp78/BiP level was quantified by densitrometic analysis of Western blots as the one shown in E, normalized for the level of actin,
and expressed as a percentage of the level in Non-Tg mice. Each bar represents the mean 6 SEM of four independent cultures.
doi:10.1371/journal.pone.0019339.g002
Prion, ER Stress and the Proteasome
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between Tg(PG14) mice that expressed or did not express Ub
G76V-
GFP, judging by a set of objective criteria [8].
Mice were culled at different stages of the Tg(PG14) illness [9],
and their brains analyzed by Western blot and immunohisto-
chemistry with anti-GFP antibodies. Western blot analysis was
done in two Tg(PG14
+/2)/Ub
G76V-GFP1
+/2 mice aged 91 days,
and one each at 98, 150, 187, 248 and 293 days. Immunohisto-
chemistry was done on two Tg(PG14
+/2)/Ub
G76V-GFP1
+/2 aged
73 days, one each at 103, 150, 187, 277, 292, 313 and 333 days,
and two Tg(PG14
+/2)/Ub
G76V-GFP2
+/2 aged 141 days, two at
214 and one at 325 days. There was no increase in the level of the
GFP reporter in Tg(PG14
+/2)/Ub
G76V-GFP
+/2 mice compared
to age-matched Tg(PG14
2/2)/Ub
G76V-GFP
+/2 and Tg(WT
+/2)/
Figure 3. Mutant PrP transgenic mice show no increase in Grp78/BiP and CHOP/GADD153 immunoreactivity in the brain. (A–C)
Immunohistochemical detection of Grp78/BiP in human colon adenocarcinoma (A), and in the hippocampus of a 504-day-old female Tg(WT) (B) and a
751-day-old female Tg(CJD) mouse with terminal disease (C). (D–F) Immunohistochemical detection of CHOP/GADD153 in human colon
adenocarcinoma (D), and in the cerebellar cortex of the Tg(WT) mouse shown in B (E) and a 367-day-old male Tg(PG14) mouse with terminal disease
(F). Note the reduced number of cerebellar granule neurons in the Tg(PG14) mouse. M, molecular layer; P, Purkinje cell layer; G, granule cell layer;
GrDG, granular zone of the dentate gyrus. Scale bar =50 mm.
doi:10.1371/journal.pone.0019339.g003
Figure 4. Regulation of PrP expression in PC12 Tet-on cells. (A) PC12 Tet-on cells transfected with WT (top panel) or PG14 (lower panel) PrP
were treated with the doses indicated of doxycycline (dox) and lysed after 24 h. Lysates corresponding to 50 mg of proteins were analyzed by
Western blot using the 3F4 antibody. (B) Cells were induced with 0.25 mg/ml dox for the indicated times and analyzed as in A. Molecular mass
markers are in kDa. Similar results were obtained with clones of PC12 cells transfected with M128V, D177N/M128 or D177N/V128 PrPs (not shown). U,
unglycosylated; M, monoglycosylated; H, highly glycosylated. Note that PG14 PrP has a higher molecular mass because of the 72-amino acid
insertion.
doi:10.1371/journal.pone.0019339.g004
Prion, ER Stress and the Proteasome
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G76V-GFP
+/2 controls (Fig. 8 and 9). As previously reported
[8,9], mice expressing PG14 PrP showed marked atrophy of the
cerebellum due to synaptic loss in the molecular layer and
apoptosis of granule neurons (Fig. 9, compare panels C, D with A,
B); this was not associated with any increase in immunoreactivity
for GFP (Fig.9, comparepanel G withEand F; and KwithI and J).
Specific GFP-immunopositivity was detected in Purkinje neurons
in the cerebellum of Tg(PG14
+/2)/Ub
G76V-GFP1
+/2 mice ex-
pressing higher reporter levels (Fig. 9G). However, this was also
detected in Tg(PG14
2/2)/Ub
G76V-GFP1
+/2 and Tg(WT
+/2)/
Ub
G76V-GFP1
+/2 mice (Fig. 9E and F), and was therefore
independent of mutant PrP expression.
Next we assessed UPS activity in cultured transgenic neurons
expressing D177N PrP. Primary CGN from Tg(CJD) mice and
nontransgenic littermates were incubated with an internally
quenched fluorogenic peptide, carrying a proteasome-specific
cleavage motif fused to the TAT sequence and linked to the
fluorophores EDANS and DABCYL (TED) [36]. The TED
peptide penetrates cell membranes and is rapidly cleaved by the
proteasomal chymotrypsin-like activity. Proteasomal cleavage
leads to physical separation of the EDANS/DABCYL pair,
abolishing intramolecular quenching, and EDANS fluorescence
increases proportionally to the amount of substrate cleaved. Thus,
proteasomal efficiency can be directly assessed by counting
fluorescent cells by optical microscopy. The percentages of
fluorescent neurons were comparable in Tg(CJD) and nontrans-
genic cultures, indicating that basal proteasome activity was not
altered in cells expressing mutant PrP (Fig. 10A). The proteasome
inhibitor epoxomycin had similar potency in Tg(CJD) and
nontransgenic neurons (Fig. 10A).
ER stress activates a ‘‘pre-emptive’’ quality control system that
aborts PrP translocation, allowing its proteasome-mediated
degradation in the cytosol [19,20]. Under chronic ER stress the
proteasome may be overwhelmed [37], resulting in accumulation
and aggregation of PrP in the cytosol [38]. Cytosolic PrP oligomers
may inhibit proteasome activity [21], triggering a feedback loop
leading to further PrP accumulation in the cytosol and cell death
[39,40]. We used two different approaches to test whether
accumulation of untranslocated PrP aggregates was associated
with low proteasome function. We treated hippocampal neurons
from Ub
G76V-GFP mice with tunicamycin to induce ER stress and
untranslocated PrP (Fig. 10B, lane 4) [19], and monitored
Ub
G76V-GFP accumulation by live cell imaging and immuno-
staining with an anti-GFP antibody. Ub
G76V-GFP was readily
detectable in cells treated with the proteasome inhibitor MG132,
but not with tunicamycin (Fig. 10C), indicating that cytosolic
accumulation of untranslocated PrP did not inhibit proteasomal
degradation of Ub
G76V-GFP. Next, we assessed proteasome
activity in cells treated with a cyclopeptolide (C-741) that inhibits
PrP translocation [41,42], producing a biologically active form of
cytosolic PrP [42]. Hippocampal neurons from C57BL/6 mice
were incubated with or without C-741 for 24 h. MG132 was
added during the last 6 h of treatment to induce robust
accumulation of untranslocated PrP in the cytosol of C-741-
treated cells [42], and proteasome activity was measured using the
TED peptide. We found no significant differences in proteasome
function between cells treated with MG132 alone or together with
C-741 (Fig. 10D), although the latter accumulated cytosolic PrP
(Fig.10E, lane 6).
Discussion
Secretory and membrane proteins are subject to a stringent
surveillance mechanism that causes retention of misfolded forms in
the ER preventing them from reaching the cell surface. Retained
proteins can stimulate ER stress response pathways, such as the
UPR, which transmits information to the cytosol and nucleus to
improve protein folding capacity, inhibit protein synthesis and
translocation, and favor misfolded protein catabolism through
ERAD. Since PrP
Sc and other forms of pathogenic PrP are likely
to be structurally distinct from PrP
C, one might expect these
molecules to be recognized as ‘‘abnormal’’ by the ER quality
control machinery and trigger ER stress. Persistent ER stress may
lead to apoptosis [14], a cell death modality that is often observed
in experimental and natural prion diseases.
ER stress was proposed to play a key role in prion diseases since
stress-regulated ER chaperons, such as Grp78/BiP and Grp58/
Erp57, were induced in sporadic and variant CJD, and in bovine
spongiform encephalopathy, and their up-regulation correlated
with disease progression in prion-infected mice [38,43,44,45,46].
Treatment of neuroblastoma N2a cells with PrP
Sc purified from
infected hamsters induced Grp78/BiP, Grp58/Erp57 and Grp94,
and activated caspase-12, a protein involved in ER stress-induced
apoptosis [44]. Similar changes were observed in cortical neurons
treated with synthetic PrP peptide 106–126, an experimental tool
used to model PrP
Sc neurotoxicity [47].
However, the cellular mechanism by which PrP
Sc could cause
stress in the ER is not clear. PrP
Sc propagates itself by imprinting
its aberrant conformation on endogenous PrP
C, generating
additional molecules of PrP
Sc in an autocatalytic reaction
Figure 5. Mutant PrPs acquire abnormal biochemical proper-
ties in PC12 Tet-on cells. (A) Cells transfected with WT, M128V,
D177N/M128, D177N/V128 or PG14 PrP were induced with 1 mg/ml dox
for 24 h before lysis. 100 mg of protein extract was ultracentrifuged for
40 min at 186,000 x g to separate the soluble (S) and insoluble (P)
protein fractions, and PrP was analyzed by Western blot using antibody
3F4. (B) Cells transfected with WT or mutant PrPs were induced with
1 mg/ml dox for 24 h before lysis. 300 mg of protein extract was
digested with the indicated concentrations of PK and analyzed by
Western blot using antibody 3F4. The bracket indicates the bands
corresponding to PK-resistant PrP.
doi:10.1371/journal.pone.0019339.g005
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endocytic compartment [50,51,52], so it is unlikely to be the
proximate cause of stress in the ER. Exposure of N2a cells to
purified PrP
Sc induced fast, sustained calcium release from ER
stores [44], suggesting that perturbation of ER calcium homeo-
stasis might be the actual trigger. Regardless of the precise
mechanism by which PrP
Sc stimulates ER stress, the fact that
genetic ablation of XBP1 or caspase-12 does not modify the onset
or progression of symptoms in prion-infected mice [53,54]
indicates that this pathway is not essential for prion diseases
acquired by infection.
ER stress, however, might play a pathogenic role in genetic
prion diseases, in which the mutant PrP molecules misfold
spontaneously in the ER lumen [55]. In the present study we
measured the levels of several ER stress markers in transgenic mice
and cells expressing PG14 and D177N PrPs. These mutant
molecules accumulate in the neuronal secretory pathway [12], and
their expression is associated with swelling of the ER cisternae
([10] and unpublished observations), a morphological alteration
often associated with the UPR [56]. Unexpectedly, molecular
biology, biochemical and immunohistochemical analyses of brain
tissue and primary neurons from the mutant mice did not find
evidence of an ER stress response. Analysis of transiently
transfected HEK-293 cells or PC12 cells in which PrP expression
was switched on only at the time of the experiment to rule out
adaptation to mutant PrP gave similar results. Thus, chronic or
acute mutant PrP expression was not associated with ER stress in
transgenic models, consistent with evidence from genetic prion
disease patients [57].
How might the lack of an ER stress response be explained
despite demonstrable mutant PrP misfolding in this organelle?
There is evidence that pathogenic mutations, including D178N,
do not perturb the overall fold of PrP [58] but stabilize partially
structured folding intermediates [59], which might elude the
quality control system in the ER. We did in fact find that PG14
and D177N PrP were not diverted to ER-associated degradation
[11,12], but eventually trafficked to post-Golgi compartments [55]
from which they are probably routed to the endo-lysosomal system
for degradation [60].
Although ER stress does not appear to be a causative
mechanism in prion diseases, perturbation of ER homeostasis
might contribute to the pathogenesis. Treatment of N2a cells with
several ER stressors caused formation of a PrP
C isoform that was
more prone to PrP
Sc-induced in vitro misfolding, suggesting that
ER-damaged neurons may be more susceptible to prion
replication [61]. Furthermore, ER stress could compromise UPS
functionality [37] and damage cells by favoring formation of
cytosolic PrP oligomers that might further inhibit proteasome
function [21,38,40].
To investigate the contribution of proteasome impairment in
genetic prion diseases, we measured the UPS efficiency in
Tg(PG14) mice. As these mice age they progressively accumulate
an oligomeric form of mutant PrP in the CNS [62], and develop
massive apoptotic degeneration of cerebellar granule neurons
[9]. This might reflect a gradual loss of the efficiency of the
proteasomal degradation system due to build-up of toxic PrP
aggregates in the cytosol. Analysis of UPS activity in vivo using
the Ub
G76V-GFP reporter did not find specific alterations at any
stage of the Tg(PG14) disease. Neither was any loss of UPS
efficiency found in neurons expressing D177N PrP, using an
innovative fluorogenic peptide for monitoring proteasomal
proteolytic activity in live cells. Thus neurodegeneration in the
transgenic models is not associated with perturbation of the
cytosolic proteasomes, in line with evidence that mutant PrP is
Figure 6. Mutant PrPs levels are lower on the surface of PC12 cells and co-localize with an ER marker. (A) PC12 Tet-on cells transfected
with WT, PG14, D177N/M128 or D177N/V128 PrP were induced with 1 mg/ml dox for 24 h. Cells were incubated with 3F4 antibody without
permeabilization to detect PrP on the cell surface (panels a–d) or fixed and permeabilized before incubation with 3F4 to visualize intracellular PrP too
(panels e–h). Scale bar =10 mm. (B) Low-magnification images of PC12 Tet-on cells transfected with WT, PG14 and D177N/V128 after
permeabilization and immunofluorescence staining of PrP. Scale bar =20 mm. D177N/M128 PrP gave similar results (not shown). (C) PC12 Tet-on cells
transfected with WT, PG14, D177N/M128 PrPs were differentiated with 100 ng/ml NGF, and PrP expression was induced with 1 mg/ml dox for 24 h.
Cells were fixed, permeabilized and stained with mouse monoclonal anti-PrP antibody 3F4 (panels a, d and g) and rabbit anti-calnexin antibody
(panels b, e and h) followed by Alexa 488(green)-conjugated anti-mouse and Alexa 546(red)-conjugated anti-rabbit secondary antibodies. Merged
images are shown in panels c, f and i. Scale bar =10 mm. D177N/V128 PrP gave similar results (not shown).
doi:10.1371/journal.pone.0019339.g006
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was no loss of proteasome function when PrP was forced to
aggregate in the cytosol by a drug that inhibits co-translational
translocation. This, and the observation that untranslocated PrP
caused no toxicity to neurons [12,42], strongly argues against the
idea that neuronal death in prion diseases is due to cytosolic PrP
accumulation.
UPS function was reduced in prion-infected mice [21,63], but
only at an advanced stage of disease and in brain regions with the
most intense neuropathology, suggesting that proteasome impair-
ment is a secondary event rather than a primary pathogenic
trigger. Moreover, proteasome activity was not reduced in scrapie-
infected sheep – in fact, it was higher than in uninfected animals –
indicating that low UPS function is not an obligatory correlate of
prion pathology [64].
The results here indicate that PG14 and D177N mutants do
not activate ER stress-mediated pro-apoptotic mechanisms, nor
do they inhibit the proteasomal degradation pathway. Then,
Figure 7. Mutant PrP expression does not trigger ER stress response in PC12 Tet-on cells. (A) Two clones of PC12 Tet-on cells transfected
with WT (lanes 1–4), D177N/M128 (lanes 5–8) or PG14 PrP (lanes 9–12) were left untreated (2) or induced for 24 h with 1 mg/ml dox (+); 20 mg of total
RNA was analyzed by Northern blot using Grp78/BiP-(top panel) and GAPDH-(lower panel) specific probes. The D177N/V128 mutant did not behave
differently from the D177N/M128 and so is not included in this figure. (B) Cells transfected with PG14 PrP were left untreated (2) or treated (+) for
24 h with 1 mg/ml dox, with or without 1 mg/ml tunicamycin (Tm). Total RNA was extracted for Northern blot analysis with a CHOP-specific probe
(top panel). Sister cells were lysed for Western blot analysis with antibody 3F4 to verify induction of PrP expression and the effectiveness of
tunicamycin, demonstrated by the appearance of a single band corresponding to unglycosylated PrP (lower panel). Clones transfected with D177N/
M128 or D177N/V128 PrP gave the same result so are not included in this figure. (C) Cells transfected with WT or D177N/M128 PrP were left untreated
(2) or treated (+) for 24 h with 1 mg/ml dox, with or without 1 mg/ml Tm, or with Tm but not dox. Total RNA was extracted and XBP1 splicing was
analyzed by RT-PCR. Each product of amplification was separated on 2.5% agarose gel. Spliced forms were detected only in samples treated with
tunicamycin. Clones transfected with M128V, PG14 or D177N/V128 PrP gave the same result so are not included in this picture. (D) Cells transfected
with PG14 PrP were treated with 1 mg/ml dox for 24 h (panels a and b) or with tunicamycin (panel c), and analyzed by immunofluorescence with
mouse monoclonal anti-PrP antibody 3F4 (panel a) and rabbit anti-CHOP antibody (panels b and c) followed by Alexa 488(green)-conjugated anti-
mouse and Alexa 546(red)-conjugated anti-rabbit secondary antibodies. Panels a and b show the same field. Clones transfected with D177N/M128 or
D177N/V128 PrP gave the same result. Scale bar =10 mm.
doi:10.1371/journal.pone.0019339.g007
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their maturation in the ER, PG14 and D177N PrPs eventually
reach the cell surface [11]. Molecules that reach the surface
become aggregated and PK-resistant [55], and might damage
cells by altering membrane properties or interacting abnormally
with other proteins on the plasma membrane [3,65]. Alterna-
tively, intracellular aggregation of mutant PrP might interfere
with vesicular traffic impairing delivery of essential cargo
molecules to synapses. We did in fact find that D177N PrP
expression in N2a cells is associated with an alteration of the
Figure 8. Tg(PG14) mice do not accumulate Ub
G76V-GFP in their brains. The hippocampus (Hipp), cerebral cortex (Cx) and cerebellum (Cb)
were dissected from a 181-day-old Tg(WT
+/2)/Ub
G76V-GFP1
+/2 (lanes 1, 5 and 9), a 187-day-old Tg(PG14
2/2)/Ub
G76V-GFP1
+/2 (lanes 2, 6 and 10), a
Tg(PG14
+/2)/Ub
G76V-GFP1
+/2 (lanes 3, 7 and 11), and a Tg(PG14
+/2)/Ub
G76V-GFP1
2/2 (lanes 4, 8 and 12) mouse, and analyzed by Western blot (100 mg
protein per lane) with antibody 3F4 which detects transgenic but not endogenous PrP (top panel), and anti-GFP antibody (lower panel).
doi:10.1371/journal.pone.0019339.g008
Figure 9. Cerebellar degeneration in Tg(PG14) mice is not associated with proteasome impairment. Sections from Tg(WT
+/2)/Ub
G76V-
GFP1
+/2 (A, E), Tg(PG14
2/2)/Ub
G76V-GFP1
+/2 (B, F), Tg(PG14
+/2)/Ub
G76V-GFP1
+/2 (C, G) and Tg(PG14
+/2)/Ub
G76V-GFP1
2/2 mice (D, H); Tg(WT
+/2)/
Ub
G76V-GFP2
+/2 (I), Tg(PG14
2/2)/Ub
G76V-GFP2
+/2 (J), Tg(PG14
+/2)/Ub
G76V-GFP2
+/2 (K) and Tg(PG14
+/2)/Ub
G76V-GFP2
2/2 (L) mice were stained with
anti-GFP antibody. Mice were 292 (A–D), 150 (E–H), and 325 (I–L) days old. Aged PG14 PrP-expressing mice show marked atrophy of the cerebellum
(C, D). Purkinje neurons of mice expressing the Ub
G76V-GFP1 transgene (E–G) show specific GFP immunopositivity (not seen in the Ub
G76V-GFP1
2/2
mouse in panel H), irrespective of the PrP genotype. M, molecular layer; P, Purkinje cell layer; G, granule cell layer. Scale bar in D (applicable to
A–D)=500 mm; scale bar in L (applicable to E–L)=200 mm.
doi:10.1371/journal.pone.0019339.g009
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Finally, PG14 and D177N PrP misfolding may affect calcium
homeostasis ([67] and A. Senatore and R.C. unpublished
observations) with possible consequences on intracellular signal-
ing and neurotransmission.
In conclusion our analyses do not support a role for ER stress
and/or UPS dysfunction in prion diseases. Elucidating the
proximate cause of neuronal dysfunction and degeneration in
these disorders remains an open challenge.
Materials and Methods
Mice
Production of transgenic mice expressing wild-type, PG14 and
D177N/V128 mouse PrPs with an epitope for the monoclonal
antibody 3F4 has been reported [8,10]. In this study we used
transgenic mice of the Tg(WT-E1
+/+) line, which express ,4X the
endogenous PrP level, referred to throughout the text as Tg(WT),
as well as Tg(PG14-A3
+/2), and Tg(D177N/V128-A21
+/2)
Figure 10. Expression of D177N PrP or accumulation of cytosolic PrP is not associated with reduced proteasome function. (A)
Cultures of CGN from Tg(CJD) mice (CJD) and nontransgenic littermates (NT) were left untreated or exposed to 5 mM epoxomycin for 3 h, and
incubated with 40 mM TED for 20 min to measure proteasome activity. Fluorescence-positive cells were quantified by optical microscopy. Data are
the mean 6 SEM of three independent experiments. (B) Cultures of hippocampal neurons from Ub
G76V-GFP2
+/2 mice were left untreated (CT) or
exposed to 5 mg/ml tunicamycin (Tm) for 24 h. Cell were lysed and centrifuged at 186,000 x g for 40 min, and PrP in the supernatants (S) and pellet (P)
was visualized by immunoblotting with antibody 12B2. The arrow indicates the band corresponding to untranslocated PrP. Molecular mass markers
are in kilodaltons. (C) Hippocampal neurons from Ub
G76V-GFP2
+/2 mice were left untreated or exposed to 20 mM MG132 for 5 h or 5 mg/ml
tunicamycin (Tm) for 24 h, then fixed and reacted with an anti-GFP antibody (green), and DAPI (blue) to stain the nuclei. Scale bar =100 mm. (D)
Hippocampal neurons from C57BL/6J mice were left untreated or exposed to 10 mM C-741 for 18 h to inhibit PrP translocation; 20 mM MG132 was
added during the last 6 h to induce accumulation of untranslocated PrP. Fluorescence-positive cells were quantified after 20 min incubation with
TED. Data are the mean 6 SEM of three independent experiments. (E) Untransocated PrP was visualized by immunoblotting as in B.
doi:10.1371/journal.pone.0019339.g010
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Tg(CJD), respectively. These mice were originally generated on a
C57BL/6J X CBA/J hybrid and were then bred with the Zurich I
line of Prnp
0/0 mice [68] with a pure C57BL/6J background
(European Mouse Mutant Archive, Monterotondo, Rome, Italy;
EM:01723). The Ub
G76V-GFP1 and Ub
G76V-GFP2 mouse lines
expressing the transgene from a chicken b-actin promoter with a
cytomegalovirus immediate early enhancer [32] were maintained
by breeding with C57BL/6J mice.
Double transgenic mice expressing PrP and Ub
G76V-GFP were
generated by breeding Tg(WT
+/+) or Tg(PG14
+/2) with Ub
G76V-
GFP mice (of both the Ub
G76V-GFP1 and Ub
G76V-GFP2 lines).
The offspring was screened by PCR for the presence of the
transgenes as described [8,32]. Tg(PG14
+/2)/Ub
G76V-GFP
+/2
mice were analyzed with equal numbers of age-matched controls.
These included Tg(PG14
2/2)/Ub
G76V-GFP
+/2, Tg(PG14
+/2)/
Ub
G76V-GFP
2/2, and Tg(WT
+/2)/Ub
G76V-GFP
+/2.
Development of neurological illness in PG14 PrP-expressing
mice was scored according to a set of objective criteria [8].
Cerebellar degeneration was analyzed by histology as described
[9,22].
Ethics Statement
All procedures involving animals were conducted according to
European Union (EEC Council Directive 86/609, OJ L 358,1;
December 12, 1987) and Italian (D.L. n.116, G.U. suppl. 40,
February 18, 1992) laws and policies, and were in accordance with
the United States Department of Agriculture Animal Welfare Act
and the National Institutes of Health Policy on Humane Care and
Use of Laboratory Animals. They were reviewed and approved by
the Mario Negri Institute Animal Care and Use Committee that
includes ad hoc members for ethical issues (18/01-D, 18/01-C).
Animal facilities meet international standards and are regularly
checked by a certified veterinarian who is responsible for health
monitoring, animal welfare supervision, experimental protocols
and review of procedures.
Neuronal Cultures
Primary neuronal cultures were prepared as previously
described [69]. Briefly, cerebella were dissected, sliced into ,1-
mm pieces and incubated in Hank’s balanced salt solution (HBSS,
Gibco) containing 0.3 mg/ml trypsin (Sigma) at 37uC for 15 min.
Trypsin inhibitor (Sigma) was added to a final concentration of 0.5
mg/ml and the tissue was mechanically dissociated by passing
through a flame-polished Pasteur pipette. Cells were plated at
350–400,000 cells/cm
2 on poly-L-lysine (0.1 mg/ml)-coated
plates. Cells were maintained in Basal Medium Eagle (Gibco)
supplemented with 10% dialyzed fetal bovine serum (FBS, Sigma),
penicillin/streptomycin and KCl 25 mM, at 37uCi na n
atmosphere of 5% CO2, 95% air.
Hippocampal neurons were prepared from two-day-old animals
as described [69]. Brain tissue was sliced into ,1-mm pieces and
incubated in HBSS (Gibco) containing 20 U/ml papain (Sigma) at
34uC for 30 min. Trypsin inhibitor (Sigma) was added to a final
concentration of 0.5 mg/ml and the tissue was mechanically
dissociated by passing through a flame-polished Pasteur pipette.
Cells were plated at 150–250,000 cells/cm
2 on poly-D-lysine-
coated (25 mg/ml) plates and maintained in Neurobasal Basal
Medium (Gibco) supplemented with B27 (Gibco), penicillin/
streptomycin and glutamine 2 mM. To reduce the number of non-
neuronal cells, aphidicolin (3.3 mg/ml, Sigma) was added to the
medium 48 h after plating. Non-neuronal contamination was less
than 3%.
Cell lines
PC12 Tet-on cells expressing the reverse tetracycline-controlled
transactivator (rtTA) [26] were grown on poly-L-lysine-coated
dishes in Dulbecco’s modified Eagle’s medium (DMEM, Sigma)
supplemented with 10% FBS (Sigma) and 5% horse serum (HS,
Sigma) tested for the absence of tetracycline-derived contaminants,
at 37uC in a 5% CO2 atmosphere. To induce neuronal
differentiation cells were seeded on dishes coated with rat tail
collagen, and grown in DMEM containing 1% HS, 100 ng/ml
NGF (Harlan) and 200 mM 8-(4-chlorophenylthio)adenosine39:59-
cyclic monophosphate sodium salt (CPT-cAMP, Roche). Cells
were used after 7 days, when 80% of cells were differentiated, as
judged by neurite outgrowth.
Construction of cDNAs encoding wild-type (M128, WT),
M128V, D177N/M128, D177N/V128 or PG14 PrP carrying
an epitope tag for the monoclonal antibody 3F4 has been
described [12,70]. Pst I and Not I restriction sites were inserted
respectively upstream of the 59 and downstream of the 39 ends of
the PrP open reading frame by PCR, using Vent polymerase (New
England Biolabs) and the following primers: 59-GACCAGCTG-
CAGATGGCGAACCTTGGCTACTGGCTG-39 (sense); 59-GA-
CCAGGCGGCCGCTCATCCCACGATCAGGAAGATGAG-39
(antisense). The amplification products were cloned into the Pst I/
Not I restriction sites of the bidirectional Tet vector pBI-G (BD
Clontech), containing the tetracycline-responsive element (TRE),
and their identity was confirmed by sequencing the entire coding
region.
PC12 Tet-on cells were plated on 100-mm dishes, left to reach
80% confluence and transfected with 0.8 mg of pBI-G empty or
containing the PrP cDNA (WT, M128V, D177N/M128, D177N/
V128 or PG14), 8 mg of pTeT-tTS encoding for a transcriptional
silencer (tTS) that blocks transcription of genes under control of
the TRE in the absence of dox, and 0.1 mg of pTK-Hyg encoding
for hygromycin resistance, using Lipofectamine Plus reagent
(Invitrogen Inc., Carlsband, California). Three days after trans-
fection, hygromycine (80 mg/ml, Sigma) was added to the culture
medium. Resistant clones were isolated four weeks after exposure
to hygromycin and tested for PrP expression before and after
induction with 1 mg/ml dox for 24 h by immunoblotting with the
3F4 antibody. Only clones with undetectable basal expression of
transfected PrP were selected for further experiments. The data
presented here were obtained from at least two cloned lines
expressing each construct.
HEK (human embryonic kidney)-293 cells (A.T.C.C.; CRL-
1573) were grown in a 1:1 mixture of MEM (minimal essential
medium)-a and DMED containing 10% FBS, 2 mM glutamine,
non-essential amino acids and penicillin/streptomycin. Cells were
transfected with pcDNA3.1 plasmids encoding WT or mutant
PrPs [12], or the m-chain of mouse IgM-H [28], using
Lipofectemine
TM 2000 (Invitrogen).
Antibodies
Anti-PrP mouse monoclonal antibody 3F4 [71] was diluted
1:200 for immunofluorescence and 1:5,000 for Western blot, and
12B2 [72] 1:2,500 for Western blot. A rabbit polyclonal antibody
against calnexin was used 1:100. A rabbit polyclonal antibody
against GFP (Molecular Probes) was used 1:2,500. A rabbit
polyclonal anti-CHOP/GADD53 antibody (Santa Cruz Biotech-
nology) was used 1:50 for immunofluorescence and 1:800 for
immunohistochemistry. Anti-KDEL and anti-Grp58/Erp57
mouse monoclonal antibodies (Stressgen) were used 1:1,000. An
anti-pan-actin monoclonal antibody (Chemicon) was used
1:20,000. A goat polyclonal anti-Grp78/BiP antibody (Santa
Cruz Biothecnology) was used 1:200 for immunohistochemistry. A
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(Santa Cruz Biotechnology) was used 1:5,000 to detect murine
Ig-m-chains by Western blot.
XBP1 Splicing
Total RNA was extracted using RNAwiz (Ambion), according
to the manufacturer’s instructions. RNA samples were reverse-
transcribed with MuLV Reverse Transcriptase (Applied Biosys-
tems) by priming with oligo(dT). XBP1 mRNA was amplified
with primers flanking the 26b intron (59-GGAGTGGAG-
TAAGGCTGGTG and 59-CCAGAATGCCCAAAAGGATA)
and PCR products resolved on 2.5% agarose gels [19].
Northern Blot
Northern blot analysis was done using the CDP-Star Chemi-
luminescent Detection System (Amersham Biosciences). 20 mgo f
total RNA was separated by electrophoresis on 1.25% agarose gel
containing 6% formaldehyde and transferred onto a nylon
membrane (Hybond-N+, Amersham Biosciences) by capillary
elution for 18 h, then immobilized by baking the membrane for
2 h at 80uC. Mouse PrP (wild-type, 3F4 tagged), hamster CHOP,
mouse Grp78/BiP and mouse GADPH (glyceraldehyde-3 phos-
phate-dehydrogenase) cDNAs were used as a template for the
preparation of fluorescein-labeled probes using the Gene Images
Random-Prime Labeling module (Amersham Biosciences). The
RNA blot was rinsed in SSC 2X (sodium chloride sodium citric
acid), pre-hybridized for 2 h at 60uC in hybridization buffer (SSC
5X, 5% dextrane sulphate, 0.1% sodium dodecyl sulphate (SDS),
100 mg/ml denatured salmon sperm DNA, and 10% Liquid Block
provided in the Gene Images Blot Kit, Amersham Biosciences)
and hybridized for 18 h at 60uC with the labeled probe. Excess
probe was removed by washing once with SSC 2X, 0.1% SDS for
15 min at room temperature, once with SSC 1X, 0.1% SDS for 15
min at 65uC, and once with SSC 0.5X, 0.1% SDS for 15 min at
65uC. The membrane was pre-incubated with 5% non-fat dried
milk (NFDM) in 0.1 M Tris-HCl, pH 9.5, 0.3 M NaCl (blocking
buffer) for 2 h at room temperature before incubating with
alkaline phosphatase-conjugated anti-fluorescein antibody (1:5,000
in blocking buffer) for 1 h at room temperature. Unbound
antibody was removed by rinsing four times with 0.1 M Tris-
HCl, pH 9.5, 0.3 M NaCl, 0.3% Tween-20. The membrane was
incubated for 5 min with the CDP-Star substrate (Amersham
Biosciences) and the chemiluminescent signal visualized with a
Biorad XRS image scanner or Hyperfilm-MP films (Amersham
Biosciences).
Biochemical Analysis
To test the detergent insolubility of PrP, cells were lysed in 10
mM Tris pH 7.5, 100 mM NaCl, 0.5% sodium deoxycholate and
0.5% Nonidet P-40 containing protease inhibitors (1 mg/ml
pepstatin and leupeptin, 0.5 mM phenylmethylsulfonyl fluoride
(PMSF), and 2 mM ethylenediaminetetraacetic acid). Lysates
corresponding to 300 mg of protein were centrifuged at 186,000 x g
for 40 min in a Beckman Optima Max-E ultracentrifuge. Proteins
in the pellet and supernatant were separated by SDS-polyacryl-
amide gel electrophoresis and electro-transferred onto polyvinyli-
dene fluoride membranes (Immobilon P, Millipore). Membranes
were incubated first with 5% NFDM in 100 mM Tris pH 7.5, 150
mM NaCl and 0.1% Tween 20 (TTBS), then with anti-PrP
antibodies overnight at 4uC or for 1 h at room temperature, rinsed
three times with TTBS and incubated for 1 h at room temperature
with horseradish peroxidase-conjugated secondary antibody
(diluted 1:5,000; Santa Cruz). Signals were revealed using
enhanced chemiluminescence (Amersham Biosciences), and visu-
alized by a Biorad XRS image scanner. Quantitative densitometry
of protein bands was done using Quantity One software (Biorad).
To test PK resistance 300 mg of protein extracts were digested
with 0.25–0.5 mg/ml of PK for 30 min at 37uC. Digestion was
terminated by adding PMSF to a final concentration of 5 mM.
Proteins were methanol-precipitated and PrP was analyzed by
Western blot using the 3F4 antibody.
Immunofluorescence
PC12 cells were seeded on poly-L-lysine-coated glass coverslips
in 24-well plates at 50% confluence and induced to express PrP by
treating them with 1 mg/ml dox for 24 h. Alternatively, cells were
differentiated with NGF before proceeding with immunofluores-
cence. For surface staining of PrP, living cells were incubated with
anti-PrP 3F4 antibody (1:500 in OptiMEM) for 1 h at 4uC,
washed with ice-cold PBS and fixed in 4% paraformaldehyde
(PFA) for 1 h at 4uC. After washing with PBS, cells were incubated
in blocking solution (0.5% BSA and 50 mM NH4Cl in PBS) for
1 h at room temperature, then with Alexa 488(green)-conjugated
goat anti-mouse IgG (Molecular Probes) (1:500 in blocking
solution). After 1 h incubation at room temperature cells were
rinsed and mounted in FluorSave (Calbiochem Corporation, San
Diego, California). To visualize intracellular PrP and other
intracellular antigens, cells were washed with PBS and fixed in
4% PFA for 1 h at 4uC. Cells were then rinsed, permeabilized with
0.1% Triton X-100 for 2 min and incubated for 30 min at room
temperature in blocking solution, then with the primary antibody
(in blocking solution) for 1 h. Cells were rinsed in 0.1% Tween-
20/PBS and incubated with Alexa 488(green)- or 546(red)-
conjugated secondary antibody before mounting. For co-localisa-
tion experiments, anti-PrP antibody was incubated, followed by
the corresponding secondary antibody, before proceeding with
organelle markers staining. Cells were analyzed with an Olympus
FV500 laser confocal scanning system.
Immunohistochemistry
For CHOP/GADD153 and Grp78/Bip immunostaining,
sections from paraffin-embedded, 4% PFA-fixed tissue were
collected on collagen-coated slides and stained using an automated
immunostaining system (Leica). Endogenous peroxidase activity
was blocked with 0.3% H2O2 for 20 min at room temperature.
Primary antibodies were applied to slides for 30 min at room
temperature, then incubated with horseradish peroxidase-labeled
anti-rabbit or anti-goat Envision polymers (Dako) for 30 minutes.
The reaction product was developed using 3,3-diaminobenzidine.
For GFP immunostaining, anesthetized mice were intracardially
perfused with 4% PFA; their brains were removed, post-fixed and
frozen at -80uC after cryoprotection. Brain sections were cut using
a Leica cryostat and incubated for 1 h at RT with 10% normal
goat serum (NGS), 0.1% Triton X-100 in phosphate-buffered
saline (PBS) then overnight at 4uC with the anti-GFP antibody.
After incubation with an anti-rabbit IgG biotinylated antibody
(Vector Laboratories) immunostaining was developed using the
avidin-biotin-peroxidase complex (Vector Laboratories) and
diaminobenzidine (Sigma). Images were acquired using an
Olympus image analyzer and the Cell-R software.
Proteasome activity in single cells
Proteasome activity was assessed in living neuronal cells using
the TED peptide, as described [36]. Briefly, neurons grown in 15-
mm slide 8-well chamber dishes (Ibidi) were incubated with 40 mM
TED in Krebs Ringer Hepes (KRH) buffer (125 mM NaCl, 5 mM
KCl, 1.2 mM MgSO4, 2 mM CaCl2, 10 mM glucose, 25 mM
Hepes, pH 7.4) for 20 min. The TED solution was replaced with
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with a Cell
R imaging station (Olympus) coupled to an inverted
microscope (IX 81, Olympus) equipped with an incubator to
maintain constant temperature (37uC) and CO2 (5%). The
EDANS fluorescent signal was acquired with a high-resolution
camera (ORCA) equipped with a 340-nm excitation filter
(D340xv2 Chroma), a 400-nm dichroic mirror (400DCLP,
Chroma) and an emission filter with a range of 510640 nm
(D510/40 m, Chroma). Images were acquired after 20 min of
incubation, and ten frames were randomly sampled for a
minimum of 1000 cells. EDANS-positive cells, identified after
removing background, were counted and compared to the total
cell number counted by bright-field using the ImageJ 1.43 software
(http://rsbweb.nih.gov/ij/).
Supporting Information
Figure S1 Mutant PrP expression does not trigger ER
stress response in HEK-293 cells. (A, B) HEK-293 cells were
transfected with the empty pcDNA3 plasmid (Vec) or with
plasmids encoding WT, D177N/M128, D177N/V128, PG14
PrP, or the heavy-chain of mouse IgM (Ig-m) and lysed after 24 h.
Lysates corresponding to 30 mg of proteins were analyzed by
Western blot using the 3F4 antibody. Molecular mass markers are
in kDa. (C) Total RNA was extracted from transfected HEK-293
cells, and XBP1 splicing was analyzed by RT-PCR. Each product
of amplification was separated on 2.5% agarose gel. Spliced forms
were detected only in cells expressing the m-chain or treated with
tunicamycin (Tm). Size markers are given in base-pairs.
(TIF)
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